利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

30 条记录 (耗时 0.027 秒)

    Therapeutic agent for allergic dermatitis
    1.
    发明授权
    Therapeutic agent for allergic dermatitis 失效
    过敏性皮炎的治疗剂

    公开(公告)号：US06201011B1

    公开(公告)日：2001-03-13

    申请号：US09242894

    申请日：1999-02-26

    申请人： Hiroaki Shirahase ,  Akihisa Yoshimi ,  Shohei Nakamura ,  Mamoru Kanda

    发明人： Hiroaki Shirahase ,  Akihisa Yoshimi ,  Shohei Nakamura ,  Mamoru Kanda

    IPC分类号： A01N4316

    CPC分类号： C07D311/24 ,  A61K31/352 ,  Y10S514/886

    摘要： A therapeutic agent for allergic dermatitis caused by type IV allergic reaction, which contains diethyl L-lysylcromoglycate of the formula: or a nontoxic salt thereof as an active ingredient. This therapeutic agent for allergic dermatitis is effective for the treatment of allergic dermatitis caused by type IV allergic reaction, such as contact dermatitis mainly induced by type IV allergic reaction and atopic dermatitis induced by type I and type IV allergic reactions.

    摘要翻译： 由IV型过敏反应引起的过敏性皮炎的治疗剂，其包含下式的二乙基L-赖氨酰色甘酸酯或其无毒盐作为活性成分。 这种过敏性皮炎治疗剂对于治疗由IV型过敏反应引起的过敏性皮炎，如主要由IV型过敏反应引起的接触性皮炎和I型和IV型过敏反应引起的特应性皮炎是有效的。

    Medicinal use of cromoglycic acid compounds
    2.
    发明授权
    Medicinal use of cromoglycic acid compounds 失效
    药用色甘酸化合物

    公开(公告)号：US06262108B1

    公开(公告)日：2001-07-17

    申请号：US09555751

    申请日：2000-07-28

    申请人： Hiroaki Shirahase ,  Akihisa Yoshimi ,  Shohei Nakamura ,  Mamoru Kanda ,  Fumio Fukata

    发明人： Hiroaki Shirahase ,  Akihisa Yoshimi ,  Shohei Nakamura ,  Mamoru Kanda ,  Fumio Fukata

    IPC分类号： A61K3135

    CPC分类号： C07D311/24 ,  A61K31/352

    摘要： The cromoglycic acid compound of the formula (I) has an antirheumatic action, an antiinflammatory action and an immunomodulating action. This compound is effective for the inhibition of the symptoms of chronic rheumatoid arthritis and is associated with fewer side effects. Therefore, the antirheumatic agent of the present invention can be used beneficially for the treatment of rheumatoid arthritis. In addition, this compound has anti-type I and anti-type IV allergic activities. Therefore, the compound can be used beneficially mainly for the treatment of allergic dermatitis, in which a type IV allergic reaction is involved, such as contact dermatitis, in which a type IV allergic reaction is involved, atopic dermatitis, in which type I and type IV allergic reactions are involved and the like.

    摘要翻译： 式（I）的色甘酸化合物具有抗风湿作用，抗炎作用和免疫调节作用。 该化合物对于抑制慢性类风湿性关节炎的症状是有效的，并且与副作用较少有关。 因此，本发明的抗风湿剂可有益地用于治疗类风湿性关节炎。 此外，该化合物具有抗I型和抗IV型过敏活性。 因此，该化合物可以有益地用于治疗涉及IV型过敏反应的过敏性皮炎，例如涉及IV型过敏反应的接触性皮炎，特应性皮炎，I型和型 涉及IV过敏反应等。

    Heterocyclic derivatives, method of production thereof and pharmaceutical use thereof
    3.
    发明授权
    Heterocyclic derivatives, method of production thereof and pharmaceutical use thereof 有权

    公开(公告)号：US06204392B1

    公开(公告)日：2001-03-20

    申请号：US09283525

    申请日：1999-04-01

    申请人： Hiroshi Matsui ,  Shoji Kamiya ,  Hiroaki Shirahase ,  Shohei Nakamura

    发明人： Hiroshi Matsui ,  Shoji Kamiya ,  Hiroaki Shirahase ,  Shohei Nakamura

    IPC分类号： C07D20926

    摘要： Heterocyclic derivatives of the formula (I) wherein each symbol is as defined in the specification, pharmaceutically acceptable salts thereof and method of producing them. Pharmaceutical compositions containing the heterocyclic derivative or a pharmaceutically acceptable salt thereof, particularly, ACAT inhibitors and lipoperoxidation inhibitors. The heterocyclic derivatives and pharmaceutically acceptable salts thereof of the present invention show superior ACAT inhibitory activity and lipoperoxidation inhibitory activity, and are useful as ACAT inhibitors and hyperlipemia inhibitors. To be specific, they are useful for the prevention and treatment of arteriosclerotic lesions of arteriosclerosis, hyperlipemia and diabetes, as well as ischemic diseases of brain, heart and the like.

    Heterocyclic derivatives, method of production thereof and pharmaceutical use thereof
    6.
    发明授权
    Heterocyclic derivatives, method of production thereof and pharmaceutical use thereof 失效
    杂环衍生物，其制备方法和药物用途

    公开(公告)号：US06414012B1

    公开(公告)日：2002-07-02

    申请号：US09373163

    申请日：1999-08-12

    申请人： Hiroshi Matsui ,  Shoji Kamiya ,  Hiroaki Shirahase ,  Shohei Nakamura ,  Katsuo Wada

    发明人： Hiroshi Matsui ,  Shoji Kamiya ,  Hiroaki Shirahase ,  Shohei Nakamura ,  Katsuo Wada

    IPC分类号： A61P910

    CPC分类号： C07D231/12 ,  A61K31/404 ,  A61K31/47 ,  C07D209/08 ,  C07D215/06 ,  C07D215/26 ,  C07D233/56 ,  C07D249/08 ,  C07D401/12 ,  Y10S514/824 ,  Y10S514/866

    摘要： Heterocyclic derivatives of the formula (I) wherein each symbol is as defined in the specification, pharmaceutically acceptable salts thereof and method of producing them. Pharmaceutical compositions containing the heterocyclic derivative or a pharmaceutically acceptable salt thereof, particularly, ACAT inhibitors and lipoperoxidation inhibitors. The heterocyclic derivatives and pharmaceutically acceptable salts thereof of the present invention show superior ACAT inhibitory activity and lipoperoxidation inhibitory activity, and are useful as ACAT inhibitors and hyperlipemia inhibitors. To be specific, they are useful for the prevention and treatment of arteriosclerotic lesions of arteriosclerosis, hyperlipemia and diabetes, as well as ischemic diseases of brain, heart and the like.

    摘要翻译： 式（I）的杂环衍生物，其中每个符号如说明书中所定义，其药学上可接受的盐及其制备方法。 含有杂环衍生物或其药学上可接受的盐，特别是ACAT抑制剂和脂质过氧化抑制剂的药物组合物。 本发明的杂环衍生物及其药学上可接受的盐显示出优异的ACAT抑制活性和脂质过氧化抑制活性，并且可用作ACAT抑制剂和高脂血症抑制剂。 具体而言，它们可用于预防和治疗动脉硬化，高脂血症和糖尿病的动脉硬化病变，以及脑，心脏等的缺血性疾病。

    Heterocyclic derivatives and pharmaceutical use thereof
    7.
    发明授权
    Heterocyclic derivatives and pharmaceutical use thereof 失效
    杂环衍生物及其药物用途

    公开(公告)号：US06200988B1

    公开(公告)日：2001-03-13

    申请号：US09506839

    申请日：2000-02-18

    申请人： Shoji Kamiya ,  Hiroaki Shirahase ,  Hiroshi Matsui ,  Shohei Nakamura ,  Katsuo Wada

    发明人： Shoji Kamiya ,  Hiroaki Shirahase ,  Hiroshi Matsui ,  Shohei Nakamura ,  Katsuo Wada

    IPC分类号： C07D21540

    CPC分类号： C07D209/08

    摘要： A heterocyclic derivative of the formula (I) wherein each symbol is as defined in the specification, and pharmaceutically acceptable salts thereof. The compound (I) of the present invention and pharmaceutically acceptable salts thereof exhibit superior ACAT inhibitory activity and lipoperoxidation inhibitory activity in mammals, and are useful as ACAT inhibitors and lipoperoxidation inhibitors. Specifically, they are useful for the prophylaxis and treatment of arteriosclerosis, hyperlipemia, arteriosclerosis in diabetes, and cerebrovascular and cardiovascular ischemic diseases.

    摘要翻译： 式（I）的杂环衍生物，其中每个符号如说明书中所定义，及其药学上可接受的盐。 本发明的化合物（I）及其药学上可接受的盐在哺乳动物中表现出优异的ACAT抑制活性和脂过氧化抑制活性，可用作ACAT抑制剂和脂质过氧化抑制剂。 具体地说，它们可用于预防和治疗动脉硬化，高脂血症，糖尿病中的动脉硬化，以及脑血管和心血管缺血性疾病。

    Indolyl or indolinyl derivatives and medicinal use thereof as ACAT or lipid peroxidation inhibitors
    8.
    发明授权
    Indolyl or indolinyl derivatives and medicinal use thereof as ACAT or lipid peroxidation inhibitors 失效
    吲哚基或二氢吲哚衍生物及其作为ACAT或脂质过氧化抑制剂的药用

    公开(公告)号：US6063806A

    公开(公告)日：2000-05-16

    申请号：US51202

    申请日：1998-04-03

    申请人： Shoji Kamiya ,  Hiroaki Shirahase ,  Hiroshi Matsui ,  Shohei Nakamura ,  Katsuo Wada

    发明人： Shoji Kamiya ,  Hiroaki Shirahase ,  Hiroshi Matsui ,  Shohei Nakamura ,  Katsuo Wada

    IPC分类号： C07D209/08 ,  A61K31/40 ,  C07D209/12 ,  C07D209/14 ,  C07D209/18

    CPC分类号： C07D209/08

    摘要： A heterocyclic derivative of the formula (I) ##STR1## wherein each symbol is as defined in the specification, and pharmaceutically acceptable salts thereof. The compound (I) of the present invention and pharmaceutically acceptable salts thereof exhibit superior ACAT inhibitory activity and lipoperoxidation inhibitory activity in mammals, and are useful as ACAT inhibitors and lipoperoxidation inhibitors. Specifically, they are useful for the prophylaxis and treatment of arteriosclerosis, hyperlipemia, arteriosclerosis in diabetes, and cerebrovascular and cardiovascular ischemic diseases.

    摘要翻译： PCT No.PCT / JP96 / 02852 Sec。 371日期：1998年4月3日 102（e）1998年4月3日PCT PCT 1996年9月30日PCT公布。 公开号WO97 / 12860 PCT 日期1997年4月10日一种式（I）的杂环衍生物，其中每个符号如说明书中所定义，及其药学上可接受的盐。 本发明的化合物（I）及其药学上可接受的盐在哺乳动物中表现出优异的ACAT抑制活性和脂过氧化抑制活性，可用作ACAT抑制剂和脂质过氧化抑制剂。 具体地说，它们可用于预防和治疗动脉硬化，高脂血症，糖尿病中的动脉硬化，以及脑血管和心血管缺血性疾病。

    Imidazole derivative, pharmaceutical use thereof, and intermediate therefor
    10.
    发明授权
    Imidazole derivative, pharmaceutical use thereof, and intermediate therefor 失效
    咪唑衍生物，其药物用途及其中间体

    公开(公告)号：US5538973A

    公开(公告)日：1996-07-23

    申请号：US393042

    申请日：1995-02-23

    申请人： Hiroshi Matsui ,  Shoji Kamiya ,  Hiroaki Shirahase ,  Shohei Nakamura

    发明人： Hiroshi Matsui ,  Shoji Kamiya ,  Hiroaki Shirahase ,  Shohei Nakamura

    IPC分类号： C07D521/00 ,  A61K31/495 ,  A61K31/445 ,  C07D401/14 ,  C07D403/14

    CPC分类号： C07D249/08 ,  C07D231/12 ,  C07D233/56

    摘要： An imidazole derivative of the formula (I) ##STR1## wherein each symbol is as defined in the specification, or a pharmacologically acceptable salt thereof is described. A method for producing the compound or its salt, and its pharmaceutical use, particularly as an agent for the prophylaxis and treatment of the diseases induced by thromboxane A.sub.2 or histamine are described. Also, compounds of the formula (II) and (IV) ##STR2## wherein each symbol is as defined in the specification are described. The imidazole derivative and its parmacologically acceptable salt are useful as agents for the prophylaxis and treatment of the diseases induced by thromboxane A.sub.2 or histamine, and the intermediate compounds (II) and (IV) are novel compounds.

    摘要翻译： 其中每个符号如说明书中所定义，或其药理学上可接受的盐的式（I）的咪唑衍生物。 描述了化合物或其盐的制备方法及其药物用途，特别是作为预防和治疗由血栓素A2或组胺引起的疾病的药剂。 此外，描述了其中每个符号如说明书中所定义的式（II）和（IV）的化合物（IMAGE）（II）（IV）。 咪唑衍生物及其分子间可接受的盐可用作预防和治疗由血栓素A2或组胺诱导的疾病的药剂，中间体化合物（II）和（IV）是新化合物。